Table 1.
Tall-Cell Variant Versus All Papillary Thyroid Carcinoma Cases
| Parameter | TCV | All PTC | TCV vs. all PTC |
|---|---|---|---|
| Patients | 278 | 2522 | |
| Mean follow-up (months) | 28.0 (26.0–30.0) | 26.1 (25.3–26.8) | p = 0.28 |
| Mean age | 54.3 (52.4–56.2) | 46.3 (45.5–47.1) | p < 0.0001 |
| Age ≥ 45 years | 69.8% (64.5–75.1) | 50.1% (49.9–50.3) | p < 0.0001 |
| Male | 25.5% (20.4–30.6) | 26.1% (24.6–27.7) | p = 0.84 |
| Gross extrathyroidal extension | 53.6% (50.6–56.6) | 30.2% (29.3–31.1) | p < 0.0001 |
| Mean tumor size (mm) | 25.9 (23.9–27.9) | 27.1 (26.1–28.1) | p = 0.28 |
| Cervical metastases | 39.6% (33.9–45.3) | 36.5% (34.6–38.4) | p = 0.35 |
| Distant metastases | 8.3% (5.0–11.5) | 13.1% (11.8–14.4) | p = 0.021 |
| Adjuvant RAI treatment | 55.0% (49.2–60.8) | 48.8% (46.9–50.7) | p = 0.05 |
Patient and tumor characteristics: TCV and all PTC cases. Data expressed as mean with 95% confidence interval.
PTC, papillary thyroid carcinoma; RAI, radioactive iodine; TCV, tall-cell variant.